Today, we’re presenting data from our Phase 2b/3 trial of an investigational drug in patients with diabetic macular edema (DME). Learn more: go.msd.com/~2va

Today at #EADVCongress, we shared positive Phase 2b results evaluating our investigational anti-TL1A biologic in adults with moderate to severe hidradenitis suppurativa (HS). Learn more: go.msd.com/~nel

Join us today at 9 a.m. ET to learn more about our Q2 2026 #earnings: go.msd.com/~6q2

Our Q2 2026 #earnings results are live: go.msd.com/~e4u Swipe below for perspective from Chairman and CEO Rob Davis.

Today we announced our initial post-approval access plans for our investigational HIV prevention option. We are accelerating our access planning to help ensure that, if approved by the regulatory agency, this HIV prevention option can be accessed by those who need it in low- and middle-income countries. Learn more: go.msd.com/~3wv

Every day, our scientists tackle challenging problems like the scalable synthesis of complex molecules. In this latest publication in Science Magazine, we share how we’re using #biocatalysis to manufacture orally available macrocyclic peptides. Learn more: go.msd.com/~q3y

Today, MSD completed the acquisition of Terns Pharmaceuticals, further strengthening our #oncology portfolio and reinforcing our focus on science‑driven innovation. Learn more: go.msd.com/~0bd

Join us today at 9 a.m. ET to learn more about our Q1 2026 #earnings: go.msd.com/~qh7

Our Q1 2026 #earnings results are live. Check out our full financial summary and key highlights: go.msd.com/~uw0

We’re proud to partner with Google Cloud to help shape the future of biopharmaceutical innovation with AI-enabled enterprise transformation. This collaboration is about unlocking new value: accelerating discovery, modernizing how we work and empowering our teams to focus on the highest-impact science and solutions for patients. Learn more about the landmark partnership: go.msd.com/~7q2

Today we announced the initiation of a pivotal Phase 2b/3 trial for the treatment of patients with neovascular age-related macular degeneration (#wetAMD). Learn more: go.msd.com/~n4o #ophthalmology

We’re sharing Phase 3 results of our investigational oral macrocyclic peptide. Learn more: go.msd.com/~lx0

Today, we announced an agreement to acquire Terns Pharmaceuticals, adding a potential best-in-class candidate for the treatment of certain patients with chronic myeloid #leukemia (#CML) to our growing #hematology pipeline: go.msd.com/~dpo9lg

Join us today at 9 a.m. ET to learn more about our Q4 and full-year 2025 #earnings: go.msd.com/~3kr

Our Q4 and full-year 2025 #earnings results are live. Check out our full financial summary and key highlights: go.msd.com/~vk8

Today, we announced the completion of the acquisition of Cidara Therapeutics, diversifying our pipeline with a novel late-phase antiviral candidate being evaluated for the prevention of symptomatic influenza in certain individuals at high risk of complications. Learn More. msd.gl/4svGbC3

Today, we signed a most favored nations agreement with the Trump administration. Addressing global pricing imbalances through a fair, value-based approach is essential, and this agreement helps us do that responsibly, while improving access for U.S. patients at an affordable price. A key component of this agreement is ensuring access to our investigational oral PCSK9 inhibitor being evaluated in patients with elevated cholesterol. Once approved, this medicine will be available through a direct-to-patient program making it easier to get at affordable prices. Over time we hope to be able to broaden access to this important medicine globally at affordable prices. msd.gl/492OKLE

We’re excited to share new data from our neuroscience pipeline at CTAD 2025, including results for two #AlzheimersDisease candidates. The U.S. FDA has granted Fast Track Designation to one of our candidates for the treatment of Alzheimer's. Learn more: msd.gl/4q0zeXV

Today, we announced an agreement to acquire Cidara Therapeutics, Inc., diversifying our respiratory portfolio to include an investigational long-acting strain-agnostic antiviral agent. msd.gl/49U4Ycb